Key Stats for PG Stock
- Past week performance: -1.3%
- 52-week range: $138 to $167
- Valuation model target price: $180
- Implied upside: 22.7% over 2.8 years
Stress test P&G’s cost headwind assumptions with TIKR’s free Valuation Model (It’s free) >>>
A Steady Quarter, a Big Bet on Wellness
Procter & Gamble (PG) shares have traded in a narrow range this week as investors digest a fiscal year that came in largely as expected but a fiscal 2027 outlook that carries real cost pressure. The consumer staples giant closed fiscal 2026 with organic sales growth of 1%. Core earnings per share reached $6.89, up 1% year over year. Nine of ten product categories held or grew organic sales for the fiscal year. Hair care along with skin and personal care each grew mid single digits.
The bigger story is what comes next. P&G guided fiscal 2027 organic sales growth to a range of 1% to 3%. Core EPS growth guidance sits at 0% to 3%, both modest by the company’s historical standards. Management flagged a roughly $1 billion after tax cost headwind. The headwind ties to higher raw materials, energy, and transportation costs. Much of it links to Middle East conflict premiums on oil prices. First quarter EPS is expected to fall 5% or more year over year before conditions ease later in the fiscal year.
CFO Andre Schulten told investors the outlook reflects higher raw materials, energy, and transportation costs. Other premiums flowing through the supply chain also weigh on the forecast. To offset some of that pressure, P&G agreed in early August to acquire premium supplements brand Thorne. The brand was on pace for roughly $650 million in 2026 sales. The acquisition gives P&G a foothold in a faster growing wellness category.
Going forward, the key question for investors is whether Thorne’s growth can offset near term margin pressure. That pressure is already baked into fiscal 2027 guidance from management.
Compare P&G’s cost headwinds against its own margin history (It’s free) >>>
Is PG Stock Undervalued?
Under valuation model assumptions realized through 6/30/29, the stock is modeled using:
- Revenue Growth (CAGR): 2.8%
- Operating Margins: 24.1%
- Exit P/E Multiple: 21.0x
Based on these inputs, the model estimates a target price of $180, implying 22.7% total upside from the current share price and a 7.5% annualized return over the next 2.8 years.
That 7.5% figure sits in modest territory rather than deeply undervalued, which fits a defensive consumer staples stock facing real cost inflation. Revenue growth assumptions of 2.8% are conservative but realistic given P&G’s own guidance for 1% to 3% organic growth, and operating margins near 24% reflect some compression from the input cost headwinds management has flagged repeatedly. The Thorne acquisition does not move the needle much on these top-line assumptions yet, since its roughly $650 million in expected sales is a rounding error against P&G’s $87 billion revenue base.
What matters more for the valuation case is whether P&G can protect its exit multiple. A 21x forward earnings multiple is reasonable for a stable dividend payer, but it leaves little room for error if input costs stay elevated longer than the first half of fiscal 2027. Investors betting on this stock are effectively betting that productivity savings and pricing power offset commodity inflation over time.
See how P&G’s margin assumptions compare across scenarios (Free with TIKR) >>>
P&G Versus Its Consumer Staples Peers
Colgate-Palmolive (CL) is P&G’s closest direct comparison in household and personal care, and it just reported Q2 organic sales growth of 2.4%, within its full-year guidance range of 1% to 4%, similar to P&G’s own 1% to 3% target. Colgate’s gross margin expanded 140 basis points in the quarter to 61.5%, notably higher than P&G’s roughly 51% LTM gross margin, though Colgate is a smaller company more concentrated in oral and personal care.
Kimberly-Clark (KMB) offers a starker contrast. The diaper and tissue maker recently cut its annual forecast after quality claims in China hurt diaper sales, a reminder that even large, established consumer names can face abrupt demand shocks tied to reputational issues rather than macro trends. That kind of disruption has not hit P&G directly, but it underscores the category-specific risks that sit alongside the broader input cost pressure P&G itself is navigating.
Against both peers, P&G’s scale and diversified category mix give it more room to absorb shocks than either rival, but its growth guidance is now roughly in line with, rather than ahead of, smaller competitors like Colgate.
What’s Driving PG Stock Going Forward?
The most immediate catalyst is how quickly the $1 billion cost headwind eases through fiscal 2027. Management has been explicit that the first half of the year carries the bulk of the pressure, tied to an assumed $90 per barrel Brent crude oil price, so any relief in energy or freight costs during the back half could meaningfully improve the earnings trajectory versus current guidance.
The Thorne acquisition is the other major thread to watch, since it signals P&G’s intent to expand further into premium wellness beyond its existing OTC drug portfolio, which includes Pepto-Bismol and Metamucil. The deal is expected to close later in fiscal 2026 or early fiscal 2027 pending regulatory approval, and how quickly P&G integrates Thorne’s practitioner-focused distribution model will determine whether the category becomes a meaningful growth driver or stays a small bolt-on.
Restructuring efforts tied to brand and product form rationalization remain an ongoing drag, contributing 30 to 50 basis points of headwind to organic sales guidance. As those changes work through the portfolio, investors should watch for sequential improvement in U.S. and China performance, two markets management specifically flagged as priorities heading into fiscal 2027.
Build your own P&G recovery scenario (Free with TIKR) >>>
Should You Invest in Procter & Gamble?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up PG, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track PG alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze PG stock on TIKR Free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
